Evidence map›Paper›PMID 36131214›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2023

Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC

Xiao Li, Joke Bilcke, Alike W van der Velden, Robin Bruyndonckx, Samuel Coenen, Emily Bongard, Muirrean de Paor, Slawomir Chlabicz, Maciek Godycki-Cwirko, Nick Francis and 22 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 16 institutions in 14 countries.

Xiao LiCentre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium. xiao.li@uantwerpen.be.ORCID http://orcid.org/0000-0002-1918-1791
Joke BilckeCentre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium.ORCID http://orcid.org/0000-0001-5720-5291
Alike W van der VeldenJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-9443-2837
Robin BruyndonckxInteruniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, Hasselt, Belgium.ORCID http://orcid.org/0000-0002-4217-2869
Samuel CoenenLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1238-8052
Emily BongardThe Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5957-6280
Muirrean de PaorRCSI Department of General Practice, 123 St Stephens Green, Dublin 2, Ireland.
Slawomir ChlabiczDepartment of Family Medicine, Medical University of Bialystok, Białystok, Poland.ORCID http://orcid.org/0000-0001-5022-4588
Maciek Godycki-CwirkoCentre for Family and Community Medicine, Medical University of Lodz, Lodz, Poland.
Nick FrancisSchool of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-8939-7312
Rune AabenhusSection and Research Unit of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-9354-2236
Heiner C BucherDivision of Infectious Diseases and Hospital Hygiene, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
Annelies ColliersDepartment of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
An De SutterDepartment of Public Health and Primary Care (Centre for Family Medicine), Gent University, Gent, Belgium.ORCID http://orcid.org/0000-0002-2540-8307
Ana Garcia-SangenisUniversity Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6689-6466
Dominik GlinzDepartment of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3509-8186
Nicolay J HarbinDepartment of General Practice, Antibiotic Center for Primary Care, Institute of Health and Society, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-3005-6908
Katarzyna KosiekFamily Doctors' Clinic, Lodz, Poland.
Morten LindbækResearch Leader Antibiotic Centre for Primary Care, Department of General Practice, University of Oslo, Oslo, Norway.
Christos LionisGeneral Practice and Primary Health Care at the School of Medicine, University of Crete, Crete, Greece.ORCID http://orcid.org/0000-0002-9324-2839
Carl LlorUniversity Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6644-717X
Réka Mikó-PauerDRC Drug Research Center LLC, Balatonfüred, Hungary.
Ruta Radzeviciene JurguteFDC Mano šeimos gydytojas, Klaipeda, Lithuania.
Bohumil SeifertInstitute of General Practice, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-6881-8840
Pär-Daniel SundvallGeneral Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-9889-509X
Pia Touboul LundgrenDépartement de Santé Publique, Hôpital de l'Archet, Nice, France.
Nikolaos TsakountakisMalia Surgery, Kastelli HC, Heraklio, Greece.
Theo J VerheijJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Herman GoossensDepartment of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.
Christopher C ButlerThe Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Philippe BeutelsCentre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium.ORCID http://orcid.org/0000-0001-5034-3595
ALIC4Etrial investigators
University of Antwerp · BEUniversity of Copenhagen · DKUniversity of Oslo · NOCharles University · CZMedical University of Lodz · PLRoyal College of Surgeons in Ireland · IEUniversity Hospital of Basel · CHUniversity of Oxford · GBGhent University · BEHôpital l'Archet · FRMedical University of Białystok · PLRegion Västra Götaland · SEUniversity Medical Center Utrecht · NLUniversity of Crete · GRInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESUniversity of Southampton · GB

Funding

European Commission grant HEALTH-F3-2013-602525
6 · The paper itself

Abstract

backgroundOseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries.

methodsDirect and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed.

resultsThe healthcare payers' expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1-€35 per patient).

conclusionAdding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.

Indexed as

Influenza, HumanVirus DiseasesAdolescentAdultChildCost-Benefit AnalysisEuropeHumansOseltamivirPrimary Health CareQuality-Adjusted Life YearsQuality of LifeOseltamivirCost-utility analysisDirect costEuropeILIIndirect costMulti-countryProductivity lossesQALYTamiflu

Identifiers

PMID36131214
PMCPMC10290610
OpenAlexW4296982280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.